VERU INC. 10-Q Summary: Quarter Ended June 30, 2025
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Veru Inc. is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. The company's primary drug candidates are enobosarm (for obesity and muscle preservation) and sabizabulin (for atherosclerotic cardiovascular disease). Following the sale of its FC2 business in December 2024, the company currently has no commercial revenue and is classified as a smaller reporting company. A 1-for-10 reverse stock split was effected on August 8, 2025, and all share data in this filing has been retroactively adjusted.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Nine Months Ended June 30, 2025 | Cash Position (June 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | Cash & Equivalents: $15.0 million |
| Net Loss | $(7.33) million | $(24.18) million | Working Capital: $9.5 million |
| Operating Expenses | $8.03 million | $28.07 million | Stockholders' Equity: $15.3 million |
| Net Loss Per Share | $(0.50) | $(1.65) | Debt: $0 (Residual Royalty Agreement extinguished) |
Note: The company recorded a gain on the sale of ENTADFI assets of $0.5 million for the quarter and $2.2 million for the nine-month period. A gain on extinguishment of debt of $8.6 million was recorded in the nine-month period related to the FC2 sale.
Material Changes vs. Prior Period
- Discontinued Operations: The FC2 business was sold on December 30, 2024. Consequently, the company reported no revenue from continuing operations. The nine-month 2025 net loss includes a $4.3 million loss on the sale of the FC2 business and a $7.2 million net loss from discontinued operations.
- Debt Extinguishment: The company paid $4.2 million to settle the Residual Royalty Agreement associated with the FC2 sale, resulting in an $8.6 million gain on extinguishment of debt for the nine months ended June 30, 2025.
- Operating Expenses: Research and development (R&D) expenses decreased to $3.0 million in Q3 2025 from $4.8 million in Q3 2024, primarily due to the wind-down of the Phase 2b QUALITY clinical study. However, R&D for the nine months increased to $12.7 million from $9.5 million in the prior year due to the initiation of the study.
- Liquidity: Cash and cash equivalents decreased by approximately $9.9 million from September 30, 2024, to June 30, 2025, driven by operating cash outflows of $24.6 million, partially offset by $18.9 million in investing cash inflows from asset sales.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for twelve months following the issuance date. Current cash is insufficient to fund operations, and the company expects to raise capital through equity offerings or debt financing.
- Clinical Progress:
- Enobosarm: Positive topline results were announced for the Phase 2b QUALITY study, showing preservation of lean mass and reduction in fat regain when combined with semaglutide. The company plans to propose a Phase 3 clinical program to the FDA.
- Sabizabulin: The company is exploring development for atherosclerotic cardiovascular disease and had a pre-IND meeting with the FDA in December 2024.
- Legal Proceedings: The company is subject to multiple shareholder derivative lawsuits and a class action regarding prior statements about sabizabulin. Additionally, the purchaser of the FC2 business (Clear Future, Inc.) filed a lawsuit in August 2025 alleging breach of representations and warranties.
- Contingencies: The company has a disputed receivable of $3.9 million from The Pill Club (bankrupt) and a settlement obligation of $8.3 million with a supplier regarding sabizabulin commercialization efforts.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $15.0 million cash balance against the projected burn rate for the upcoming Phase 3 enobosarm trial and general operations.
- Financing Plans: Review the status of the Lincoln Park Capital Fund purchase agreement and the terminated Jefferies Sales Agreement to assess immediate capital raising capabilities.
- Legal Exposure: Monitor the status of the Clear Future lawsuit regarding the FC2 sale and the shareholder class action litigation.
- ONCO Receivables: Assess the collectability of the remaining promissory notes from Onconetix, Inc. (ONCO) related to the ENTADFI asset sale, which have been subject to multiple forbearance extensions.
- Regulatory Path: Confirm the FDA's feedback on the proposed Phase 3 trial design for enobosarm, as this is critical for future funding and valuation.